ICU Medical (ICUI) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.44
- Estimate
- $2.15
- Surprise
- +13.6%
- Revenue (period 2026-09-30)
- $560.4M
- Score today
- 4.7/10
Revenue source: xbrl.
How the report landed
ICU Medical (ICUI) beat the $2.15 estimate with adjusted EPS of $2.44 — a large 13.6% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ICUI Sell at 4.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +13.6% surprise compares with a +15.7% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single supplier
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $171.15
- Stop
- $159.17
The stock trades at 140.9× trailing but 17.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
ICUI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $4.19B
- P/E (fwd)
- 17.4
- P/E (ttm)
- 140.9
- 52-week range
- $113.37–$192.85
- Off 52-week high
- 11.3%
- RSI (14)
- 61
- Volume vs avg
- 0.68×
- Score today
- 4.7/10